La Jolla, CA, United States of America

Mary Elizabeth Spilker

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mary Elizabeth Spilker: Innovator in Biomarker Technology

Introduction

Mary Elizabeth Spilker is a prominent inventor based in La Jolla, California. She has made significant contributions to the field of biomarker technology, holding 2 patents that showcase her innovative approach to assessing probes and biomarkers.

Latest Patents

Her latest patents include a method and apparatus for assessing the feasibility of probes and biomarkers. This invention discloses a quantitative evaluation of biomarker-probe activity, which can be quantified and analyzed using biodistributions generated from a model. In certain embodiments, these biodistributions may be utilized to create simulated images from which quantitative thresholds can be derived. Additionally, she has developed hydroxylated contrast enhancement agents, which comprise an iron chelate with specific structural characteristics. This invention also includes a metal chelating ligand and medical formulations that utilize the contrast enhancement agent.

Career Highlights

Mary Elizabeth Spilker is associated with General Electric Company, where she has been able to apply her expertise in biomarker technology. Her work has contributed to advancements in medical imaging and diagnostics, enhancing the understanding of biomarker interactions.

Collaborations

Throughout her career, she has collaborated with notable colleagues, including John Frederick Graf and Brion Daryl Sarachan. These collaborations have further enriched her research and development efforts in the field.

Conclusion

Mary Elizabeth Spilker's innovative work in biomarker technology has made a significant impact in the medical field. Her patents reflect her dedication to advancing diagnostic methods and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…